Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report

Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report

Trastuzumab emtansina (T-DM1) is an antibody-drug conjugate directed against the HER2 for the treatment of HER2+ mestastatic breast cancer (MBC), who has previously received trastuzumab plus a taxane. According to the results of the EMILIA trial versus lapatinib plus capecitabine T-DM1 shows a...

Full description

Saved in:
Bibliographic Details
Main Authors: Patricia Miranda Romero, Roberto Marín Gil
Format: Article
Language:English
Published: Elsevier 2015-02-01
Series:Farmacia Hospitalaria
Subjects:
Breast Cancer
Trastuzumab emtansine
; Cost-effectiveness
; Lapatinib
Online Access:http://www.aulamedica.es/fh/pdf/8912.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items